Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Oncophage vs Observation in High-Risk Renal Cell Carcinoma
NCT00126178Phase 3Terminated
- Sponsor
- Agenus Inc.
- Start
- May 2005
- Primary completion
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of vitespen in renal cell carcinoma (RCC), sponsored by Agenus Inc.. Started May 2005; status: terminated.
02
Drugs
vitespen
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00126178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126178.